Supreme Court‑Ordered Panel on Pharma Marketing Faces Conflict‑of‑Interest Row Over Dr. Naresh Trehan’s Inclusion

Overview The Working Group on Access to Medicines and Treatments has objected to the appointment of Dr. Naresh Trehan , chairman of Medanta , to a panel formed under the direction of the Supreme Court . The panel is tasked with reviewing the regulatory framework for pharmaceutical marketing and the proposed UCPMP, 2024 . Key Developments The Working Group submitted a representation to the Department of Pharmaceuticals urging the removal of Dr. Trehan from the committee. The group cites potential conflict of interest arising from Dr. Trehan’s financial ties to Medanta. It references a 2018 NPPA report that flagged overcharging at Medicity‑Medanta and other hospitals. Subsequent Supreme Court proceedings and state regulator assessments in Maharashtra, Uttar Pradesh and Karnataka have highlighted high mark‑ups in hospital tariffs. Important Facts The panel’s mandate is to examine existing regulations governing pharmaceutical marketing and to recommend whether the UCPMP should be adopted. The Working Group argues that any member with direct financial stakes in a major private hospital could bias the recommendations, undermining the Supreme Court’s directive for an impartial review. UPSC Relevance Understanding this episode helps aspirants in multiple papers: GS2 (Polity) : The role of the Supreme Court in directing executive action and the importance of maintaining institutional independence. GS3 (Health & Economy) : Issues of drug pricing, hospital billing, and the need for ethical marketing in the pharmaceutical sector. GS4 (Ethics) : Conflict‑of‑interest considerations in policy‑making and the ethical standards expected of public committees. Way Forward The Working Group recommends that the Department of Pharmaceuticals reconstitute the panel by appointing a member without any direct financial link to private hospitals. This would ensure that the panel’s deliberations remain transparent, impartial, and focused on public‑health objectives such as affordable access to medicines and ethical marketing practices. Future monitoring by the NPPA and continued judicial oversight are likely to shape the final recommendations on the UCPMP.